In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.

The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.

A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.